Biotechnology company Bio-Works Technologies AB announced on Monday that it has received a Letter of Intent for a EUR652,000 order of its WorkBeads affimAb, a product used in vaccine manufacturing.
This LOI highlights growing confidence in Bio-Works' role within the biopharmaceutical industry.
WorkBeads affimAb has demonstrated strong performance across various manufacturing sites, reinforcing its value in critical production settings. The order underscores customer trust in Bio-Works' quality and innovation. Bio-Works anticipates this development will further strengthen its industry partnerships.
hVIVO completes pilot study for hMPV challenge model
Merck's Gardasil approved for males in China
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine